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Abstract
Social scientists have drawn attention to the role of hype and optimistic
visions of the future in providing momentum to biomedical innovation
projects by encouraging innovation alliances. In this article, we show how
less optimistic, uncertain, and modest visions of the future can also provide
innovation projects with momentum. Scholars have highlighted the need for
clinicians to carefully manage the expectations of their prospective patients.
Using the example of a pioneering clinical team providing deep brain sti-
mulation to children and young people with movement disorders, we show
how clinicians confront this requirement by drawing on their professional
knowledge and clinical expertise to construct visions of the future with
their prospective patients; visions which are personalized, modest, and
tainted with uncertainty. We refer to this vision-constructing work as
recalibration, and we argue that recalibration enables clinicians to manage
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the tension between the highly optimistic and hyped visions of the future
that surround novel biomedical interventions, and the exigencies of deli-
vering those interventions in a clinical setting. Drawing on work from sci-
ence and technology studies, we suggest that recalibration enrolls patients
in an innovation alliance by creating a shared understanding of how the
‘‘effectiveness’’ of an innovation shall be judged.
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Introduction
Deep brain stimulation (DBS) is a therapeutic technique that involves using
a pacemaker-like device to deliver constant, carefully targeted electrical sti-
mulation to specific areas of the brain. It was first approved as a treatment
for managing some of the symptoms of Parkinson’s (PD) in the late 1990s,
and subsequently it has been used to treat tens of thousands of individuals
worldwide. Its success has led clinicians and device manufacturers to
explore other applications for the DBS technique. In 2003, it was approved
as means for managing dystonia, a movement disorder characterized by sus-
tained and intermittent involuntary muscular contraction, which can cause
painful, crippling body postures. Although it is not a cure, being reserved
for people who no longer respond to more conventional treatments, DBS
has been heralded as a life-changing medical therapy for people with PD
or dystonia (Chou, Grube, and Patil 2011). Many of those individuals
treated with DBS have experienced notable improvements in functionality,
and some individuals have experienced dramatic improvements. Reports of
previously housebound individuals with debilitating symptoms subse-
quently gaining independence are not uncommon. Proponents argue that,
unlike the ablative therapies it has supplanted, DBS does not cause irrever-
sible damage to the brain (Ardouin et al. 1999). And while the initial cost of
DBS is high, there is emerging evidence to suggest that it may be, in the
long-term, a cost-effective treatment (Fraix et al. 2006). Indeed, DBS has
become a mainstream treatment in many countries for people with PD with
symptoms that no longer respond to medications (Talan 2009). There is
considerable hope among clinicians and device manufacturers that DBS
will prove to be a clinically effective and cost-effective intervention not
only for dystonia but also for other neurological and psychiatric disorders
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including obsessive compulsive disorder (Greenberg et al. 2006) and
depression (Mayberg et al. 2005).
Not surprisingly, DBS has been presented as a source of hope for pro-
spective patients, and like many novel biomedical interventions DBS has
become the subject of hype. Much of the media coverage of DBS, for exam-
ple, has involved ‘‘over-optimistic portrayals,’’ focusing on individual cases
that do remarkably well while ignoring the more subtle improvements expe-
rienced by the majority of patients. Such positive media portrayals often
draw upon the hopeful, positive representations produced by scientist and
innovators themselves (Gilbert and Ovadia 2011). Indeed, as Schlaepfer and
Fins (2010) have illustrated, single-case studies of DBS within the scientific
literature have highlighted positive secondary effects, even when the pri-
mary goals of the research have not been achieved. Commentators have
argued that by emphasizing positive effects and perpetuating over-
optimistic portrayals, such coverage is generating unrealistic expectations
among prospective patients, many of whom have debilitating neurological
disorders and are desperate for some form of reprieve (Racine et al. 2007).
Social scientists have noted that this hype and the over-optimistic visions
of future are an integral part of the innovation process. In effect, they pro-
vide momentum to innovation projects by attracting resources and encoura-
ging necessary alliances (Brown, Rappert, and Webster 2000). Yet these
over-optimistic constructions of the future can create challenges for clini-
cians who wish to provide novel therapies to patients. As other researchers
have noted, clinicians must attain informed consent from patients, but this
cannot be achieved if patients maintain unrealistic expectations of what the
intervention can do for them (Jox et al. 2012). Additionally, if clinical out-
comes consistently fail to match patients’ expectations, the reputation of
clinicians and the intervention itself can suffer.
There is, then, something of a tension between hyped visions of the
future that tend to circulate in some domains and provide momentum to
innovation projects, and the exigencies of integrating a novel technology
into an innovative therapy within a responsible clinical service. In this arti-
cle, we draw attention to this tension as it relates to DBS. In particular, we
explore the activities of a multidisciplinary team of clinicians providing
DBS to children and young people with dystonia. The team, which we refer
to as the pediatric motor disorder service (PMDS), is based at a children’s
hospital in the United Kingdom and is one of a few teams worldwide that
provide DBS specifically to children with a severe neurological disorder.
As we will illustrate, the clinicians feel that it is not unusual for children and
families attending the service to have unrealistic visions about what DBS
Gardner et al. 3
 by guest on May 11, 2015sth.sagepub.comDownloaded from 
can offer them. Using the PMDS as a case study, we argue that clinicians
working at the ‘‘coal-face’’ of innovation engage in a particular kind of
work with patients, which we refer to as recalibration. Recalibration
involves co-constructing a vision of the future with each patient, and
encouraging the patient to adopt that vision and thus recalibrate their expec-
tations with it. Drawing on the ‘‘sociology of expectations’’ literature (and
the emerging ‘‘sociology of low expectations’’ literature), we suggest that
recalibration (and the modest, highly personalized, and uncertain futures
that this work produces) is an important and as yet unacknowledged aspect
of translational medicine.
Innovation and Expectation
Various studies under the banner of the ‘‘sociology of expectations’’ have
explored the way in which future-orientated discourses drive and shape
innovation projects (van Lente and Rip 1998; Borup et al. 2006; Brown,
Rappert, and Webster 2000; Brown and Michael 2003; Kitzinger and Wil-
liams 2005). Much of this work has explored the construction, dissemina-
tion, and effects of hype and optimistic visions of the future, in which the
innovation and those individuals and institutions involved are presented
in a highly favorable frame. Such visions, it is argued, play a performative
role in innovation projects: optimistic, future-orientated rhetoric animates
innovation projects by encouraging the building of alliances (Borup et al.
2006; Brown, Rappert, and Webster 2000). By deploying visions of the
future (which often involve narratives of ‘‘breakthrough’’ and ‘‘discovery’’)
and generating promissory expectations, institutions can enroll a potentially
diverse array of allies into a common innovation project. Real-time repre-
sentations of the future also have structuring effects on innovation alliances:
they delineate and coordinate institutional and professional roles, and by
envisaging particular beneficial outcomes and payoffs, they prescribe
responsibilities to those involved.
The ‘‘sociology of expectations’’ literature, then, has demonstrated that
examining the construction and dissemination of such futures provides
important insights into the dynamics of innovation and social and technical
change, particularly in biomedicine (Hedgecoe and Martin 2003). While
much of the work in this area has focused on ‘‘optimistic’’ future abstrac-
tions (or hype), a small, nascent body of work has drawn attention to the
less-promissory visions of the future that accompany biomedical innovation
projects. This work has examined the nature of ‘‘low expectations’’ and
what role they might play in innovation projects as a whole. Tutton, for
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example, focuses on the biotech industry in the United States that, in order
to attract potential investors and resources, produces and circulates highly
optimistic forward-looking statements. Biotech firms are permitted to do
this by the US Securities and Exchange Commission (SEC) on the condition
that they identify and stipulate the possible risk factors that would prevent
such a future from materializing. They must, in other words, carefully con-
sider and describe all the things that could possible go wrong, and by doing
this, they can protect themselves against accusations of misleading inves-
tors and the public. These pessimistic projections are filed with the SEC,
and as Tutton notes, they employ particular words and phrasing, such as
‘‘uncertainty,’’ ‘‘we cannot predict,’’ and ‘‘may also have adverse effect.’’
Tutton suggests that these projections are not simply a matter of account-
ability. Rather, they should be seen as part of an ‘‘anticipatory regime,’’
in which companies are ‘‘forced to tack back and forth between pessimistic
and optimistic forecasts of equally conditional futures’’ (Tutton 2011, 419).
Such pessimistic projections are not performative (firms wish to avoid them
rather than enact them), but they are nonetheless an important part of the
work that must be done in order to provide momentum to a biomedical inno-
vation project.
Other scholars have noted a similar intertwining of high and low expec-
tations among the scientists and researchers involved in biomedical
research. Pickersgill, for example, explored the perspectives of neuroscien-
tists and clinicians on neuroscientific research in mental health and person-
ality disorders (Pickersgill 2011). Such research has attracted considerable
investment and is the subject of much optimism, and to some extent this
optimism was shared by scientists and clinicians working within the field.
However, Pickersgill’s respondents expressed notable ambivalence about
the potential clinical impact of neuroscience and were skeptical of the more
promissory neuroscience claims. Indeed, some suggested that such positive
coverage might actually be detrimental to the field. In large part, the
ambivalent views of clinicians were derived from their clinical understand-
ing of personality disorders and their impression that some neuroscientific
claims were simply not clinically useful. In a similar vein, Fitzgerald has
explored the perspectives of scientists working in neurobiological autism
research (Fitzgerald 2014). Again, the scientists interviewed mirrored some
of the hope and positive anticipation that was associated with autism
research more generally. Some, for example, were excited by the prospect
that technological advancements would shed light on the workings of the
brain and provide new insights into neurological and psychiatric pathology.
Yet scientists also expressed disappointment in these ‘‘wonderful new
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technologies’’ and unease about the speculative hype surrounding them.
They foresaw a complex future in which the useful contribution of neu-
roscience autism research was uncertain: indeed, they expressed low expec-
tations of the future. As with Pickersgill’s respondents, these scientists
talked about their field in what Fitzgerald refers to as ‘‘entangled registers
of both promising hope and deflated uncertainty’’ (Fitzgerald 2014, 241).
Fitzgerald suggests that this ambivalence represents an intellectual language
that enables scientists to navigate and work within the ‘‘intermediate terrain’’
of an evolving biomedical field characterized by unknowns (such as the
unknown etiology of autism). In other words, an innovation project may fail
to progress toward a clearly envisaged, optimistic future, but this does mean
that it stops dead: it is nonetheless propelled toward a future by scientists and
researchers who are both cautiously hopeful and constructively skeptical.
This nascent ‘‘sociology of low expectations’’ scholarship illustrates that
biomedical innovation projects may not simply be animated by high expec-
tations alone. Rather, the dynamism of innovation emerges from a complex
intertwining of low and high expectations; an interplay of promise, hope,
and optimism, and uncertainty, pessimism, and ambivalence. As Fitzgerald
puts it in regard to neuroscientific research, negative expectations are ‘‘not
only thickly present; they may actually be important for the maintenance of
some particularly ambiguous neuroscience projects’’ (Fitzgerald 2014,
242). Indeed, this insight aligns with Moreira and Palladino’s (2005) argu-
ment that contemporary biomedicine is shaped by two logics: the ‘‘regime
of hope’’ and the ‘‘regime of truth.’’ The former is characterized by the opti-
mistic perception that research activities are warranted by the promise of a
high-reward payoff such as a miraculous cure. The latter, on the other hand,
is characterized by ‘‘the investment in what is positively known, rather than
what can be,’’ and the belief that ‘‘most medical therapies are less effective
than claimed’’ (p. 67). Biomedical endeavors are constituted by aggregates
and modes of organizing that follow either or both of these logics: prospec-
tive patients, for example, are rallied by hope, while regulators and patient
support groups may be rallied by ‘‘truth.’’ Tutton suggests that biotech com-
panies move back and forth between the two regimes, and the work of Fitz-
gerald and Pickersgill suggests that researchers and clinicians can occupy
some sort of intermediate position by drawing on understandings from both.
In this article, we also draw attention to the complex dynamics of hope,
uncertainty, promise, and doubt that animate innovative biomedical activi-
ties. However, unlike previous work in the ‘‘sociology of (low) expecta-
tions’’ which has tended to focus on the constructed futures that animate
the early stages of research or innovation projects, this article explores the
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future-constructing work of pioneering clinicians as they work with patients
at the adoption stage of innovation. The development and dissemination of
DBS has certainly been associated with highly optimistic forward-looking
statements, but using the PMDS as a case study, we illustrate that dissemi-
nation and incorporation into clinical services also involves the careful con-
struction of visions of the future that are uncertain and less optimistic. The
PMDS clinicians carefully construct personalized, modest, and uncertain
visions of the future with their patients; a form of clinical labor that we refer
to as recalibration. Recalibration involves, we argue, enrolling patients and
their families in a regime of truth, in which the likely benefits of DBS and
its limitations, are rendered explicit. Consequently, patients and families are
prompted to rationally reflect on their orientation toward the future, and
they are encouraged to re-orientate themselves toward an expected, man-
dated future based upon diagnostic truth. This is not to say that patients and
their families are disengaged from the regime of hope: rather, hope for a
dramatic recovery remains a prominent undercurrent.
The premise of this article is that recalibration is an important component
of the innovation process, specifically in the clinical sites where novel biome-
dical projects are being translated in clinical therapies. While DBS for PD has
been widely adopted, there is still considerable uncertainty surrounding its
future as a treatment for other disorders such as dystonia. Indeed, the Nuffield
Council on Bioethics recent report Neurotechnologies: Intervening in the
Brain (2013) identified DBS as one of several highly promising neurotechnol-
ogies for which there is ‘‘a great need,’’ but which are also surrounded by
‘‘great uncertainty.’’ The report suggests thatDBSoccupies a tenuous position
between experimental therapy and routine clinical treatment. The clinicians
whowork in this terrain can be said to be clinical pioneers: the degree towhich
the benefits of novel techniques such as DBS are realized depends on their
capacity to integrate and adapt the technology into day-to-day clinical services
involving patients (Hopkins et al. 2007; Morlacchi and Nelson 2011). Recali-
bration is a vital part of this process: as we demonstrate, it enables clinicians to
manage particular institutional pressures, to protect the reputation of the team
and the technique, and it helps ensure that the innovative therapy is not brought
to a halt by its failure to live up to overly optimistic anticipations.
Methods
In this article, we draw upon data collected as part of the Wellcome Trust
funded London and Brighton Translational Ethics Centre (LABTEC)
research endeavor. This endeavor included a twelve-month ethnographic
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study of the PMDS, based at a large children’s hospital in theUnitedKingdom.
It is a multidisciplinary service that includes two neurologists, an occupa-
tional therapist, two physiotherapists, a speech and language therapist, a
specialist nurse, a clinical psychologist, and a clinical research fellow, and
a team administrator. It provides DBS to children and young people with
severe cases of either primary dystonia (in which dystonia is the only neuro-
logical pathology) or secondary dystonia such as dystonic cerebral palsies (in
which dystonia coexists alongside other neurological pathologies such as
spasticity and contractures).
Interviews were conducted and audio-recorded with each member of the
team, and observations of teammeetings and interactions with patients were
undertaken. Observations were recorded in handwritten notes. Interview
transcripts and observation noteswere subject to an iterative, thematic analysis
using Nvivo coding software. Early on during the fieldwork and the coding of
the initial data, it became apparent that team members devoted considerable
time and discussion to the management of their patients’ expectations: the
researcher (JG) thus made a concerted effort to explore this theme in greater
detail during subsequent data collection. As part of this, the researcher
observed a goal-setting session, duringwhichPMDS teammembers attempted
to manage the expectations of patients and families by encouraging them to
adopt and aim for realistic goals after the DBS system has been implanted.
In what follows, we use extracts from interviews to highlight some of the
key tensions associated with the management of expectations within the
PMDS, and then in order to illustrate aspects of recalibration work, we draw
upon observational data from a specific goal-setting session involving several
team members, a patient named Carl (pseudonym) and Carl’s mother.
This data collection project was approved by the appropriate NHS
Research Ethics Committee. Informed consent was obtained from all parti-
cipants (clinicians, parents, and patients) sixteen years of age and older, and
assent was obtained from all participants under sixteen years of age (con-
sent for their participation was obtained from their parents). Information
leaflets for children and young people were modeled on the format provided
by Alderson and Morrow (2011).
Results: Managing Expectations in DBS
Glamorous Technology: Hope and Truth in DBS
For children and their families, living with dystonia is physically and
emotionally challenging. Those with severe forms of the disorder require
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full-time care and support, and carers often require slings and hoists to
move their child. Less-severely affected children and young people who
have retained some functional abilities are easily exhausted by having to
constantly battle with their involuntary movements, and many feel self-
conscious about their appearance.
Both traditional media articles (with titles such as ‘‘Deep Brain Stimula-
tion Surgery Provides New Hope for Children,’’ Wang 2013) and social
media have framed DBS as a potentially life-changing therapy for people
with dystonia. Children and families, for example, can easily access video
recordings of dramatic clinical improvements posted on YouTube. Many
of these recordings (which have been posted by patients and their families)
contrast striking footage of shaking or rigid involuntary body movement
before the DBS implantation with seemingly relaxed and controlled body
movement after the implantation. Indeed, much of the journalism and
patient-generated social media coverage surrounding DBS for dystonia cor-
responds to the ‘‘regime of hope’’ identified byMoreira and Palladino (2005).
Clinicians within the PMDS certainly felt that such coverage created
unrealistic expectations among the families that came to see them. As the
clinical research fellow explained:
There are often misperceptions . . . the press reports the case studies that do
well—so there can be [a] perception that DBS will get [their] child to walk
(Interview).
And as the physiotherapist stated, ‘‘People often hold hopes and aspirations
particularly for something that’s kind of glamorous or technical, something
like DBS.’’ Indeed, during interviews team members often spoke about the
way in which families invested hope in DBS. They referred to this as ‘‘false
hope’’ and used terms like ‘‘misperceptions’’ and ‘‘unrealistic’’ to frame the
initial view held by patients and families and to distinguish it from their
own, ‘‘realistic’’ knowledge of what DBS could actually achieve. We can
say that the stance of the PMDS clinicians corresponds to a regime of truth
(Moreira and Palladino 2005), in which DBS is understood in terms of its
most likely impact upon the patient. Such an understanding derives, in large
part, from the clinicians’ experiences of previous clinical cases. For all
members of the team, it was vital that the ‘‘unrealistic expectations’’ of
patients and families were ‘‘managed’’ and realigned with their own under-
standing of what DBS could achieve. In other words, team members felt it
was vital that patients and their families were brought into the regime of
truth:
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Parents can come with expectations really high. They want the best for their
children, and they’re also still probably grieving: the emotions around having
a child with long term neuro disability is just unbelievable. It’s huge. And
they may come in with unrealistic expectations and sometimes DBS is the
only thing out there that they could try for that child. And then you’re having
to wind those down . . . they want their child to talk and [we] are saying we
need to rein this down (Physiotherapist Junior).
Sometimes . . . they’re communicating with the communication aid, they
have no speech, and parents are saying, ‘‘I want my child to speak.’’ I will
be speaking to them directly about that—that this is actually an unrealistic
goal and I’ll talk them through this (Speech and Language Therapist).
The imperative to ‘‘rein in’’ expectations and enroll children and families
within a regime of truth was articulated in terms of morality. The clinical
team expressed a responsibility to be clear about the limitations of DBS
with families, and thus to protect them from the emotional upset and disap-
pointment that would arise if families expected too much from DBS. As one
of the physiotherapists suggested, it was ‘‘unfair’’ to ‘‘sell DBS to
everybody’’:
We can potentially bring news [to families] that’s not always easy—being
able to be really clear about what we can’t achieve. Because we could sell
it to everybody. . . . But that would be unfair (Physiotherapist).
DBS is highly invasive and it was necessary for members of the team to be
clear with families about the limitations of DBS, so that families could
make an informed decision about whether or not to proceed with the ther-
apy. Indeed, in an era when facilitating patients’ autonomy and enabling
patients’ capacity for decision making are heralded as fundamental to ethi-
cal clinical practice, managing the expectations of patients (and bringing
them into a regime of truth) can be seen as an ethical challenge.
Additionally, the team also felt that encouraging unrealistic expecta-
tions, or ‘‘false hope,’’ would be detrimental to the clinical team: ‘‘If you
paint the most optimistic picture, you are setting yourself up for certain fail-
ure’’ (Neurologist, team meeting). If the clinical outcome did not match the
expectations of families, then the reputation of the team could become tarn-
ished and potential patients who could benefit from DBS would be discour-
aged from approaching the team. Thus, the success of the team, and indeed
the success of DBS as a viable therapy for children and young people with
dystonia, would be threatened by the ‘‘overselling’’ of DBS.
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There is, then, a tension between the exigencies of delivering a novel
clinical service, and the hyped, overly optimistic representations of DBS
that are portrayed outside of the clinic. As the clinical research fellow
states:
We had one child who six weeks after his surgery, was in the press, starting to
walk again. And that’s a very worrying thing for us. . . . Managing the expec-
tations—that can become very difficult.
Thus, as the above examples illustrate, patients arrive at the PMDS having
been exposed to a ‘‘regime of hope,’’ and PMDS clinicians believe that an
important part of their work is to bring them into a ‘‘regime of truth.’’ In the
following section, we explore this aspect of their work.
Aligning Patients with the Regime of Truth: Recalibration
We refer to the process of bringing children and their families into the
regime of truth as recalibration. The practice of recalibration requires clin-
icians to draw on their professional knowledge and clinical experience to
foresee how a particular patient may respond to an intervention, and if reca-
libration is to be successful, communicating this in a manner comprehensi-
ble to them. It is, in some respects, an example of what Callon has called
interressement (Callon 1986), a process whereby an actor attempts to
delineate and impose a role or identity on another actor or set of actors.
Interressement is a process that generates socio-technical collectives, as
an actor brings other actors and entities into a common project by defining,
coordinating and aligning their capacities. Similarly, recalibration is a pro-
cess that involves an actor (the clinician) foreseeing and delineating the
likely capacities of another actor (the patient) and imposing this vision on
them. It results in the formation of a collective involving the clinician and
patient (and often the patient’s family) based upon a shared understanding
of a likely future. The resulting calibration of expectations enables clini-
cians to obtain informed consent from their patients, and in effect it brings
patients into the innovation project. In this section, we will explore the pro-
cess of recalibration as it takes place within the PMDS.
PMDS teammembers spoke of the need to dispel the rhetoric of ‘‘a quick
fix’’ that families tended to associate with DBS and to replace it with a more
realistic vision of the future; a future with some incremental gains and pos-
sibly some setbacks. As one team member stated:
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I genuinely think we are quite good at managing expectations and I think
we’re very good at expressing that it will be a long haul, that this is not a fast,
rapid sort of change. (Occupational therapist, interview)
This requires a great deal of work from all team members:
The whole team may have an input with [managing expectations], the psy-
chologist [for example] may have to help prepare the child and the family for
accepting the likely changes. (Administrator, interview)
For the PMDS team, the key aspect to managing expectations is ‘‘goal set-
ting’’ with children and families. Several weeks before the surgical proce-
dure to implant the DBS hardware, each child and their supporting family
member, along with several members of the team, participate in a goal set-
ting session. By this stage, the therapists have conducted a range of presur-
gical assessments, and they will have discussed the patient’s case with other
members of the team. During such team discussions different kinds of infor-
mation such as official diagnoses, brain scans, and the therapists’ observa-
tions from the assessments are brought together, and a collective prediction
of how the patient will respond will be made. (While this prediction-making
process is not the focus of this article, it is worth noting that it is what Lati-
mer et al. [2006] have described as ‘‘micro-political,’’ during which certain
types of evidence and knowledge are foregrounded and prioritized.) During
the session, team members use these predictions to negotiate with patients
and families a set of goals to aim for once the DBS system has been
implanted. These are clearly defined functional goals that ideally pertain
to tasks that the child and family feel are important to them, and that team
members feel are achievable. These goals are, in other words, very much
aligned with the regime of truth; they are informed and guided by the clin-
icians’ prediction of the most likely benefits provided by DBS.
So you have to find out what their hopes are initially. You have to then really
agree what’s a realistic expectation. . . . (Clinical Research Fellow, interview)
It’s nit-picking out those functional goals that you feel could be targeted. . . .
We [establish] more functional goals to make it easier [for example] for the
care giver: seating tolerance . . . standing to get dressed. (Junior Physiothera-
pist, interview)
These goals do not entail massive or dramatic leaps of recovery (even
though a few patients do indeed experience seemingly dramatic
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improvements). Rather, they entail modest improvements in the patient’s
ability to perform specific tasks:
And what we try to do is set some quite modest goals: ‘‘Well what are the five
things you’d like to improve?’’ So is it dressing, is it how you sit in a chair?
And [we’re] saying, ‘‘Okay well how satisfied would you be if you could do
that? And how important is that to you?’’ (Clinical Research Fellow,
interview)
Thus, it is via the establishment of these clearly defined goals that team
members attempt to realign the ‘‘unrealistic’’ hopes of families with
their own ‘‘realistic’’ knowledge of how the patient is most likely to
respond.
Goal setting with children and their families involves the construction of
an imagined future in notable contrast to those overly optimistic portrayals
of DBS that circulate in the media (cf. Gilbert and Ovadia 2011). The
futures constructed during the goal-setting session are highly specific and
tailored to each child and their family, and are tainted with uncertainty.
In the process, patients and their supporting family members are encour-
aged to rationally reflect on their current limitations and their hopes for the
future.
In order to illustrate this in greater detail, we will now turn to a spe-
cific goal-setting session involving Carl, a sixteen-year-old patient with
secondary dystonia, Carl’s mother, and several members of the team
including the occupational therapist, one of the physiotherapists and the
clinical psychologist. Here we will see a specific example of recalibra-
tion as team members attempt to align Carl and his mother within a
regime of truth.
In the session, team members elucidate the tasks that Carl would ideally
like to perform. Inevitably, this involves asking patients to envisage their
future:
OT: Okay, lets think. You are going to be seventeen—what are the sorts
of things you would like to do as a seventeen-year-old?
C: I want a job!
OT: And what stops you now?
Mm: He is not able to use public transport on his own, and I have to
motivate him in the mornings, make sure he eats, gets dressed,
showers.
Gardner et al. 13
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Team members then use these tasks as the basis for establishing realistic
goals with the patient. This involves honing in on specific tasks, prompting
Carl or his mother to clearly articulate the cause of the problem:
OT: You wanted to use public transport?
C: Yes.
OT: Is this a problem because you are worried that you will attract atten-
tion or is it because you cannot physically manage?
Mm: If he has one of his ticks, it can be very difficult to get on a bus.
They throw him off his feet.
It is at this point, once the cause of the hindrance has been clarified, that
the team members will draw upon their earlier observations of the patient to
provide an opinion as to how DBS may benefit them. In Carl’s case, much
of his instability is from muscle weakness rather than dystonia, and DBS is
unlikely to directly improve his ability to use public transport.
PT: We noticed you have muscle weakness around your pelvis that DBS
won’t improve . . . I don’t think we should put this down as a goal for
DBS. . . . I think you will always find a bus, a moving platform, hard.
Here we can see how the team conveys their ‘‘realistic’’ expectations to
Carl by drawing on specific aspects of his day-to-day life. In the process of
doing this, they actively construct or forecast an expected future, which in
Carl’s case is a future where using public transport will still be difficult. As
the session continues, the imagined future acquires more specific detail:
PT: Okay, so what would you like to do?
C: Go to town with my friends. . . . It is the staggering; I want to be able
to walk down the High Street with my friends.
Psy: We need to clarify: What would it take to improve your confidence?
Would it be not falling at all? Or falling less?
C: Just less falls and less jerky movements.
Psy: So, would just a little bit of improvement, then, help with your con-
fidence, do you think?
C: Yes.
Psy: Because some people might not be happy if they still had some visi-
ble signs of the movement disorder. It is good that you think a little
improvement would help with your confidence.
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Here, Carl is being prompted by the team to envisage a personalized
future where DBS provides small improvements, but where he still has visi-
ble signs of the movement disorder. It is a modest future in which DBS does
not provide dramatic or remarkable benefits. Here is another example:
C: I would like to be able to handwrite on a clear page without making a
mark all over the page.
OT: I think your computer is your best option. DBS can maybe help you a
bit, but you won’t be able to rely on your handwriting.
And another example:
PT: Carl, tell me about shaving. Why does mum do it for you?
Carl: It pulls on my hair, it is really sore.
OT: His arm pulls away and the hair gets caught in the shaver. It is defi-
nitely the involuntary movements that are making it difficult to
shave. . . . If DBS does reduce your involuntary movements . . .
you will find it easier.
Here we see the vision that is being constructed is also tainted with
uncertainty highlighted by the phrase ‘‘If DBS is able to reduce your invo-
luntary movements. . . . ’’ Indeed, this point is emphasized in the following
extract from the end of Carl’s session, particularly in the PT’s reference to
her ‘‘gut feeling’’ about Carl’s response to DBS.
PT: Improvements with secondary dystonia are more modest. Many peo-
ple are happy regardless, they are happy that they gave it a go. Also,
it is clear that many people have higher expectations than they tend to
let on. That is why we are going over all these things so carefully, and
why we are documenting all this. Our gut feeling is that you should
expect modest gains. We won’t remove your movement disorder, but
we think we will reduce the severity and quantity of your jerky
movements.
Thus, by the end of the session the participants have collectively con-
structed a modest, uncertain, highly personal future for Carl. Carl has been
encouraged to imagine a future in which, after having the DBS system
implanted, he will still have problems using public transport, he will have
visible signs of his movement disorder, he will have to continue to rely
on his computer, and where it may be easier for him to shave. Carl, in other
words, has been encouraged to re-imagine his future in accordance with a
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regime of truth, as understood by the PMDS team members. Here, then, we
have seen the specific elements of work involved in recalibration within the
PMDS: team members prompt the patient to articulate his hopes in specific
terms, and by utilizing their professional knowledge and clinical experi-
ence, draw on these terms to communicate a personalized vision of the
future. The result of this is the establishment of a common understanding
of the patient’s likely future, and thus, the patient and supporting family
members are brought into a ‘‘regime of truth.’’
Difficulties with Managing Expectations: Undercurrents of Hope
The experiences of the PMDS team suggest that recalibration is challenging
work, particularly when it pertains to an innovative clinical intervention.
Clearly foreseeing a patient’s likely clinical response is an obvious diffi-
culty. With a novel therapy such as DBS for dystonia, there is little in the
way of established clinical knowledge that can be drawn upon to make a
prediction. As one of the team members stated:
The only way to really find out how you’re going to do is to do it, and that’s a
big challenge. So you can give guidance from our experience and try and say
what are realistic expectations, but actually I think we’re still at that stage
where we can only be very crude with that. And it’s very difficult for us to
give anything more than that. (Clinical Research Fellow, interview)
In addition to this uncertainty are differences of opinion on the effectiveness
of DBS:
There [are] differences within the team about how team members might think
someone is likely to benefit. There are team members who are more optimis-
tic and more positive than others. And I think it can be a difficult thing. (Clin-
ical Research Fellow, interview)
This lack of established knowledge is particularly problematic given that
the clinicians feel pressured to be as clear as possible with patients. As a
team member states:
[We] have to be very clear if the child is not going to walk or is not going to
talk or is not going to be able to independently do this, that and the other. That
obviously has to be made very clear. And that can be quite tricky. (Team
Administrator, interview)
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Recalibration, then, involves carefully managing the tension between
uncertainty and the imperative to be clear with patients. As we saw with the
example of Carl earlier, the PMDS clinicians manage this tension by using
phrases that highlight the provisionality of their assessment, such as ‘‘our
gut feeling is,’’ ‘‘if DBS is able to . . . ,’’ and ‘‘DBS can maybe help you
a bit.’’
Recalibration work can also be very difficult for patients and families.
Unsurprisingly, the process of moving from within a ‘‘regime of hope’’
to a ‘‘regime of truth’’ can be emotionally challenging for patients, and
PMDS team members spoke of the ‘‘sense of loss’’ (physiotherapist) expe-
rienced by families as they realized that the likely impact of DBS was not
what they had initially hoped for. The clinical psychologist spoke of this as
‘‘shocking the patient’’:
I know that the doctors and everyone else in the team are always really as
clear as they can . . . almost to the point of shocking a patient and saying, you
know, ‘‘This could happen, this could happen.’’ (Clinical Psychologist)
Yet despite the ‘‘shocking’’ experience for patients and their families, reca-
libration does not necessarily entail purging all ‘‘unrealistic’’ expectations.
Recalibration involves aligning patients and families within a regime of
truth, but an undercurrent of hope may remain. The PMDS clinicians were
well aware of this:
Really we all know secretly that whatever we say and whatever the parents
agree, when you stimulate them, they all want their child to be the one that
starts walking. (Clinical Research Fellow, interview)
I think deep down, everybody, even after doing the goals, deep down, I think
loads of people expect more. (Occupational Therapist, interview)
The goal setting session is everyone’s most important session . . . it really
makes the reality of what’s happening . . . [but] I used to see when I went
over to the surgeries [during which the DBS hardware is implanted], and the
kids would wake up and then they’d start moving again and you can see it in
their parents’ faces—they’re expecting them to be still, even though you’ve
gone over and over and over it’s not going to happen. You can see that they
were hoping that it would be a miracle (Nurse, interview).
Team members stated that if they sensed that patients and their families had
too much hope, then DBS would not be offered to them. In such cases,
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recalibration has failed: the clinicians have failed to align the expectations
of the patient or patient’s family with their own expectations. The occupa-
tional therapist describes such a case:
We had a young girl . . . she was quite a functional, delightful girl, she could
do so much. And the dad was like, ‘‘I want her to be normal because other-
wise I can’t give her to get married,’’ . . . And then that started to worry [us],
because . . . when you got into more detail he really wanted a miracle . . . we
didn’t put her through DBS because we didn’t feel that the goals were realis-
tic and we explained [this] to the family.
This specific example also hints at the importance of recalibration in the
process of medical innovation. The adoption of DBS as a therapy for chil-
dren and young people with dystonia within clinical settings depends upon
the capacity of clinicians to align patients and families with the regime of
truth—the imperative to secure informed consent and the pressure to protect
their reputation will discourage clinicians such as the PMDS team from
offering a novel therapy to those children or families who have immutably
high hopes.
Discussion: Recalibration and Innovation Work
The development and dissemination of DBS exemplify important tensions
associated with biomedicine in contemporary society (Gardner 2013). Like
many novel and highly technical biomedical developments, DBS has been
the source of considerable hype and hope, and these optimistic portrayals
and promissory futures have provided momentum to the dissemination of
the DBS technique. Yet, as we have shown in this article, the dissemination
of DBS also entails the construction of less hopeful and uncertain futures.
The pioneering clinicians integrating DBS as a therapy for children and
young people with dystonia must carefully manage the expectations of their
patients; they must carefully construct personalized, modest, and uncertain
futures during their day-to-day clinical work with patients, and enroll them
within this vision of the future. If this cannot be done to the satisfaction of
team members, then the therapy will be withheld.
By drawing attention to the construction of these modest and uncertain
futures, this article contributes to the emerging work in the ‘‘sociology of
low expectations’’ (Fitzgerald 2014; Tutton 2011; Pickersgill 2011). This
body of work has shown that innovative biomedical projects are character-
ized by intertwined discourses of hope, pessimism, and ambivalence, and
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that this complex entanglement of registers provides actors with a useful
intellectual language to pursue and work within biomedical projects, partic-
ularly those that are precarious such as neurobiological autism research
(Fitzgerald 2014). Innovation projects may be animated by the construction
of optimistic futures in the present time, but much of this work is propelled
by actors with visions of the future that can be modest, uncertain, and
ambivalent. However, while this work—like much of the work with the
sociology of expectations—has focused on the constructed futures associ-
ated with ‘‘early stage’’ innovations, this article has explored the way in
which futures are constructed and mobilized at the ‘‘late stage’’ of biome-
dical innovation; that is, the adoption stage, where a novel healthcare tech-
nique (DBS) has been translated into a clinical therapy that sits somewhere
between experimental therapy and routine clinical therapy. Using DBS as a
case study, we have illustrated that the pioneering clinicians working at this
‘‘late stage’’ of innovation also deploy visions of the future that are modest,
uncertain, and highly personalized, and which are in notable tension with
the more promissory visions of the future that circulate in the public
domain. Indeed, we suggest that the construction and communication of
these futures to prospective patients—what we have called recalibra-
tion—is a vital part of the work that is done in the late-stage of innovation.
The tension between hyped portrayals of a biomedical intervention and the
exigencies of clinical practice (such as the imperative to obtain informed
consent) necessitates labor that adjusts the expectations of patients. Recali-
bration is a process through which this occurs. We have framed this recali-
bration work as a process through which actors attempt to pull patients from
a ‘‘regime of hope,’’ in which action is orientated by the anticipation of a
‘‘high reward’’ such as a miraculous clinical outcome, into a ‘‘regime of
truth’’ in which action is oriented according to knowledge of ‘‘what is most
likely to be achieved.’’
There are, as we demonstrated with the PMDS goal-setting session, two
key aspects to recalibration: First, clinician(s) draw on their professional
knowledge and clinical expertise to foresee how the patient is most likely
to respond to the therapy, and second, they communicate this vision of the
future to the child and family in an attempt to readjust their expectations.
We have also illustrated that recalibration is challenging work. It is neces-
sary for clinicians to be as clear as possible with patients, but the novelty of
the therapy makes it difficult to anticipate the likely clinical outcome.
Patients, too, may find it very emotionally challenging to accept the future
that is being presented to them, and even if they do accept it, an undercur-
rent of hope for a miraculous clinical outcome often remains. The form that
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recalibration work takes will no doubt vary between clinical settings. The
PMDS, for example, is situated within a context that facilitates multidisci-
plinary service provision: the hospital within which they are based was spe-
cifically designed to foster interdisciplinary care, and the NHS tariff system
for pediatric services supports multidisciplinary teams. Consequently, reca-
libration within the PMDS is a multidisciplinary affair, drawing on the skill-
set and expertise of professions from several different backgrounds. While
the goal-setting session-method of recalibration used by PMDS clinicians
might be unique to them, we suggest that the key aspects of this work (fore-
seeing the likely clinical outcome and communicating this to patients) are
an important part of the clinical labor that takes place in all contexts where
clinicians are providing novel therapies based upon innovative technologies
or techniques. We also suggest that, just as hype and over-optimistic repre-
sentations provide necessary momentum to innovation projects in their
early stage, the construction of ‘‘lower’’ expectations may be necessary for
the eventual stabilization of many innovations, particularly clinical innova-
tions concerned with the management of chronic illnesses.
We suggest that recalibration can be seen as a process of enrolling the
patient within an innovation alliance. As various science and technology
studies theorists have argued, biomedical innovations emerge from, and are
shaped by, socio-technical networks that can include researchers and clin-
icians, industry, regulators, and patient-support groups (Brown andWebster
2004). The success of a biomedical project depends upon the ability of pro-
ponents to build and expand socio-technical networks by enrolling other
actors through appealing to their interests and goals (often via hype), or
as Latour has argued (Latour 1987, 113-15), by ‘‘reshuffling’’ the goals
of others who consequently feel compelled to join the network. Recalibra-
tion is a process that expands a socio-technical network (or a biomedical
project) to include patients, and it does this by ‘‘reshuffling’’ the interests
and goals of patients so that they align with what is perceived by clinicians
to be ‘‘achievable.’’
More precisely, recalibration encourages patients and families to adopt
future-orientated dispositions that are conducive to technological innova-
tion projects in an era characterized by the valorization of self-
determination and self-responsibility. Studies on the ‘‘political economy
of hope’’ have illustrated that the management and appropriation of hope
is implicated in a form of biological citizenship, in which empowered citi-
zens actively engage with researchers and clinicians, share patient experi-
ences, and make use of the media (Novas 2006; Rose and Novas 2005;
Brown 2015). Hope, then, can provide a dynamism for particular a form
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of individualistic, self-determining, and self-responsible biopolitics (Peter-
sen and Wilkinson 2014). What we see with recalibration is an attempt to
discipline and channel this dynamism into specific socio-technical projects.
A comparison between recalibration and the oncology hope scales studied
by Brown (2015) is useful here. Hope scales, Brown notes, attempt to render
a patient’s hope intelligible in such a way that it can become the focus of an
intervention. They delineate and quantify ‘‘levels’’ of hope, and they
encourage patients to engage in rational reflection. In this way, hope scales
function as a disciplinary technology: they encourage the individual to re-
orientate themselves toward an ‘‘expected,’’ mandated future based upon
diagnostic truth, and to prepare for this future accordingly. Similarly, reca-
libration is a practice in which a patient’s hopes are rendered intelligible and
then subjected to corrective adjustment, and patients and families are thus
encouraged to re-orientate themselves toward this mandated future. In this
way, patients and their future-orientated dynamism may be co-opted into
biomedical innovation projects, and consequently, such projects will be
provided with dynamism and will continue, despite their frequent failure
to match the hype that often surround them.
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